- Biotech company LBT Innovations (LBT) was up more than 14 per cent today after selling its APAS Independence platform to the Limbach Group in Germany
- Significantly, this marks the first sale of APAS Independence to Limbach's technology leader, Labor Dr Gärtner
- The sale follows a six-month evaluation of the technology and was completed by LBT's joint venture company, Clever Culture Systems
- It includes a five-year software licence for the MRSA analysis module, as well as an ongoing service contract
- APAS Independence is LBT's platform technology which automates and speeds-up culture plate screening
- LBT is still up a healthy 14.6 per cent and shares are trading for 13.8 cents each
Biotech company LBT Innovations (LBT) was up more than 14 per cent today after selling its APAS Independence platform to the Limbach Group in Germany.
The Limbach Group is made up of over 30 laboratories and is the largest network of laboratories in Germany.
Significantly, this marks the first sales of APAS Independence to Limbach's technology leader, Labor Dr Gärtner.
Labor Dr Gärtner is one of the largest and most efficient laboratories in southern Germany, offering full diagnostic services to meet demands of the local community.
The sale follows a six-month evaluation of the technology and was completed by LBT's joint venture company, Clever Culture Systems (CCS).
Read the full article on The Market Herald here: https://themarketherald.com.au/lbt-innovations-asxlbt-shares-soar-on-apas-independence-sale-2020-10-12/
